{"analyses":[{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","estimateComment":"Based on Cox regression model with Efron's method of tie handling with treatment as a covariate","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","otherAnalysisDescription":"Stratified by macrovascular invasion (Yes vs. No), α-Fetoprotein (ng/mL) (\\< 200 vs. ≥ 200) and region (China vs. ex-China) with all cells that correspond to macrovascular invasion=Yes combined.","pValue":"0.0019","pValueComment":"Log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.72","statisticalComment":"Stratified by macrovascular invasion, α-Fetoprotein and region with all cells that correspond to macrovascular invasion=Yes combined","statisticalMethod":"One-sided p-value"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.8","value":"2.7"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.8","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"TTP is the time from randomization to first documented disease progression per RECIST 1.1 by BICR, based on Kaplan-Meier method for censored data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 200 mg pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG000","title":"Pembrolizumab + BSC"},{"description":"Participants received placebo by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants based on the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years","title":"Time To Progression (TTP) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"Months"}